GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

Phase 2

Terminated

Conditions: Amyloidosis

Interventions: Drug: GSK2315698 (CPHPC)
Biological: GSK2398852 (anti-SAP mAb)

First Posted Date: 2017-02-07

Last Posted Date: 2019-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 7

Registration Number: NCT03044353

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

Phase 2

Completed

Conditions: Scleroderma, Systemic

Interventions: Drug: GSK2330811
Drug: Placebo

First Posted Date: 2017-02-02

Last Posted Date: 2021-05-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 35

Registration Number: NCT03041025

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive

Not Applicable

Completed

Conditions: Denture Retention

Interventions: Other: Negative Control
Other: Test Product
Other: Positive Contol

First Posted Date: 2017-01-31

Last Posted Date: 2018-08-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT03037307

Locations: 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC/VI 62.5/25 mcg via ELLIPTA
Drug: UMEC 62.5 mcg via ELLIPTA
Drug: Salmeterol 50 mcg via DISKUS
Drug: Placebo via DISKUS
Drug: Placebo via ELLIPTA

First Posted Date: 2017-01-27

Last Posted Date: 2020-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2696

Registration Number: NCT03034915

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Danirixin
Drug: Danirixin matching placebo
Drug: Standard of care
Drug: Rescue medication

First Posted Date: 2017-01-27

Last Posted Date: 2020-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 614

Registration Number: NCT03034967

Locations: 🇪🇸
GSK Investigational Site, Zaragoza, Spain

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)
Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)

First Posted Date: 2017-01-25

Last Posted Date: 2021-05-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 42

Registration Number: NCT03031496

Locations: 🇿🇦
GSK Investigational Site, Bloemfontein, South Africa

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Phase 2

Completed

Conditions: Anaemia

Interventions: Drug: Epoetin alfa
Drug: Daprodustat

First Posted Date: 2017-01-24

Last Posted Date: 2021-06-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 105

Registration Number: NCT03029247

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Phase 3

Completed

Conditions: Anaemia

Interventions: Drug: Daprodustat
Drug: Darbepoetin alfa
Drug: Iron therapy

First Posted Date: 2017-01-24

Last Posted Date: 2021-10-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 312

Registration Number: NCT03029208

Locations: 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom

Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: GSK3196165 Dose 1
Drug: GSK3196165 Dose 2
Drug: GSK3196165 Dose 3
Drug: Methotrexate
Drug: Placebo
Drug: Folic acid

First Posted Date: 2017-01-23

Last Posted Date: 2019-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT03028467

Locations: 🇯🇵
GSK Investigational Site, Wakayama, Japan

Long Term Special Drug Use Investigation of Mepolizumab

Conditions: Asthma

Interventions: Drug: NUCALA Injection

First Posted Date: 2017-01-23

Last Posted Date: 2021-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1000

Registration Number: NCT03028480

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy